Grifols, ES0171996087

Wall Street Zen downgraded Grifols to Hold. Grifols stock gains 2.16 percent

Published on 10/26/2026 at 09:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 2.60 percent to EUR 3.57 billion. Grifols stock costs EUR 10.39 on October 26, 2026, 2.16 percent above Xetra close.

Rating and results

On October 10, 2026, Wall Street Zen downgraded Grifols from Buy to Hold.
First-half 2026 revenue rose 2.60 percent to EUR 3.57 billion at constant currency.
Grifols stock trades at EUR 10.39 at 9:36 a.m. CET at Lang & Schwarz on October 26, 2026, 2.16 percent above the Xetra close of October 23, 2026.

Bauhaus-Poster mit geometrischen Formen und dem Schriftzug BIOTECH — Bauhaus-Poster mit geometrischen Formen und dem Wort BIOTECH repräsentiert die Branche von Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) was trading at EUR 10.39 at Lang & Schwarz on October 26, 2026 at 9:36 a.m. CET, 2.16 percent above the Xetra close of October 23, 2026 at EUR 10.17. According to MarketBeat on October 10, 2026, Wall Street Zen downgraded Grifols from Buy to Hold.

Rating change meets a stronger half

The rating change adds a cautious counterpoint to Grifols' operating figures. The company reported first-half 2026 revenue of EUR 3.574 billion, up 2.6 percent at constant currency, while net profit increased 28.7 percent to EUR 227 million. These figures come from Grifols information dated July 28, 2026.

Profitability also improved in the same period. Adjusted EBITDA reached EUR 854 million, up 2.4 percent at constant currency, with an adjusted EBITDA margin of 23.9 percent. Management kept its full-year 2026 adjusted EBITDA margin target at 25 percent or higher, according to the company materials.

Three dated stock milestones

On July 28, 2026, Grifols reported EUR 3.574 billion in first-half revenue. On October 10, 2026, Wall Street Zen cut its rating from Buy to Hold. On October 26, 2026, the stock was at EUR 10.39, up 2.16 percent against the Xetra close.

Reporting dates ahead

Barron's lists November 10, 2026 as the reporting date for third-quarter 2026 results. The same calendar lists March 4, 2027 for fiscal-year 2026 earnings.

What supports the valuation?

Analyst expectations remain materially above the Madrid share price. MarketScreener showed an average target of EUR 14.76 from 12 analysts, which places the target 42.07 percent above EUR 10.39. The gap reflects the potential investors assign to improving plasma economics, but the Hold downgrade keeps execution and balance-sheet progress central to the stock story.

Trading level remains the immediate test

Grifols operates in healthcare with a focus on plasma-derived therapies, diagnostics and related products. The first-half numbers show growth and improved profit, while the rating change highlights the market's demand for delivery against the 2026 margin objective.

Grifols was trading at EUR 10.39 at Lang & Schwarz on October 26, 2026 at 9:36 a.m. CET, 2.16 percent above the Xetra close of October 23, 2026 at EUR 10.17. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.